Clinical Trials Logo

Neuroma clinical trials

View clinical trials related to Neuroma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04378062 Terminated - Pain Clinical Trials

Pain After Proximal Digital Amputation Prevention

PAPDAP
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Finger amputations are common and may be complicated by debilitating nerve pain. This study seeks to determine if nerve pain after digital amputation can be more effectively prevented with either of two new surgical techniques-targeted muscle reinnervation (TMR) or regenerative peripheral nerve interfaces (RPNI)-compared to standard treatment by traction neurectomy (TN).

NCT ID: NCT02282917 Terminated - Meningioma Clinical Trials

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Start date: December 2015
Phase: Early Phase 1
Study type: Interventional

This will be a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in Vestibular Schwannoma (VS) and meningiomas by AR-42 in adult patients undergoing tumor resection. AR-42 is a small molecule which crosses the blood brain barrier (BBB) in rodents, but the investigators are not certain yet if it will penetrate human VS. Meningiomas are outside the BBB, but seem to be unusually resistant to all current medical treatments. The primary endpoint of the bioactivity of suppression of p-AKT by AR-42 was selected as drug activity seems more informative than bioavailability. Our preclinical data and others have shown dose dependent suppression of p-AKT by AR-42 in both VS and meningiomas.

NCT ID: NCT01345136 Terminated - Clinical trials for Neurofibromatosis Type 2

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Start date: July 1, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients. RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.